MCID: ANL017
MIFTS: 44

Anal Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 12 15 17 70
Epidermoid Anal Carcinoma 12
Carcinoma of Anal Margin 70

Classifications:



External Ids:

Disease Ontology 12 DOID:5525
NCIt 50 C9161
SNOMED-CT 67 255084004
UMLS 70 C0349534 C1412036

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology : 12 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary : Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to squamous cell papilloma and squamous cell carcinoma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Regulation of TP53 Activity. The drugs Panitumumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 31.4 TP53 CDKN2A
2 squamous cell carcinoma 31.0 TP73 TP53 PIK3CA FBXW7 CDKN2A AKT1
3 papilloma 30.7 TP53 RASSF1 CDKN2A AKT1
4 in situ carcinoma 30.6 TP53 PIK3CA CDKN2A AKT1
5 rectum adenocarcinoma 30.6 TP53 PIK3CA MLH1
6 suppressor of tumorigenicity 3 30.6 TP53 CDKN2A
7 vaginal cancer 30.4 TP53 CDKN2A
8 adenosquamous carcinoma 30.3 TP53 PIK3CA CDKN2A
9 leiomyosarcoma 30.2 TP53 MDM2 CDKN2A
10 anus cancer 30.2 ZNF599 TP53 TASOR2 RITA1 PIK3CA CDKN2A
11 lymphangioma 30.1 TP53 PIK3CA MLH1 APC
12 lymphoma 29.7 TP53 PIK3CA MGMT MDM2 CDKN2A
13 lymphoma, non-hodgkin, familial 29.7 TP53 PIK3CA MDM2 APC AKT1
14 adenocarcinoma 29.6 TP53 PIK3CA MLH1 MDM2 CDKN2A APC
15 cervical squamous cell carcinoma 29.0 TP73 TP53 RASSF1 PIK3CA MLH1 CDKN2A
16 endometrial cancer 28.3 TP53 RASSF1 PIK3CA MLH1 MGMT MDM2
17 anal canal carcinoma 11.3
18 anal canal squamous cell carcinoma 10.4
19 47,xyy 10.4
20 vulvar intraepithelial neoplasia 10.4 TP53 CDKN2A
21 ovarian seromucinous carcinoma 10.4 TP53 CDKN2A
22 human papillomavirus infectious disease 10.4 TP53 CDKN2A
23 spitz nevus 10.4 TP53 CDKN2A
24 bizarre leiomyoma 10.3 TP53 CDKN2A
25 adult malignant schwannoma 10.3 TP53 CDKN2A
26 rare tumor 10.3
27 supraglottis cancer 10.3 TP53 CDKN2A
28 atypical polypoid adenomyoma 10.3 MLH1 CDKN2A
29 adenomyoma 10.3 MLH1 CDKN2A
30 localized osteosarcoma 10.3 TP53 CDKN2A
31 malignant exocrine pancreas neoplasm 10.3 TP53 CDKN2A
32 chronic cervicitis 10.3 TP53 CDKN2A
33 thyroid lymphoma 10.3 TP53 CDKN2A
34 bladder clear cell adenocarcinoma 10.3 TP53 CDKN2A
35 ring chromosome 7 10.3 TP53 MDM2
36 ring chromosome 10.3 TP53 MDM2
37 mediastinum liposarcoma 10.3 MDM2 CDKN2A
38 keratinizing squamous cell carcinoma 10.3 TP53 CDKN2A
39 male reproductive organ benign neoplasm 10.3 TP53 CDKN2A
40 actinic cheilitis 10.3 TP53 MDM2
41 colorectal cancer, hereditary nonpolyposis, type 5 10.3 MLH1 APC
42 undifferentiated embryonal sarcoma of the liver 10.3 TP53 MDM2
43 neutropenia 10.3
44 embryonal sarcoma 10.3 TP53 MDM2
45 inflammatory liposarcoma 10.3 MDM2 CDKN2A
46 pediatric liposarcoma 10.3 TP53 MDM2
47 pancreas sarcoma 10.3 MDM2 CDKN2A
48 ovarian carcinosarcoma 10.3 TP53 PIK3CA
49 periosteal osteogenic sarcoma 10.3 TP53 MDM2
50 infiltrating angiolipoma 10.3 MDM2 CDKN2A

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to Anal Squamous Cell Carcinoma

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 MLH1 TP73
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 MLH1 TP53 TP73
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.32 MDM2 MGMT MLH1 TP53 TP73

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 AKT1 APC CDKN2A FBXW7 MDM2 MLH1
2 endocrine/exocrine gland MP:0005379 10.22 AKT1 APC CDKN2A FBXW7 MDM2 MGMT
3 homeostasis/metabolism MP:0005376 10.2 AKT1 APC CDKN2A FBXW7 MDM2 MGMT
4 cardiovascular system MP:0005385 10.19 AKT1 APC CDKN2A FBXW7 MDM2 PIK3CA
5 immune system MP:0005387 10.13 AKT1 APC CDKN2A FBXW7 MDM2 MLH1
6 digestive/alimentary MP:0005381 10.11 APC CDKN2A FBXW7 MDM2 MLH1 RASSF1
7 embryo MP:0005380 10.1 AKT1 APC CDKN2A FBXW7 MDM2 PIK3CA
8 mortality/aging MP:0010768 10.06 AKT1 APC CDKN2A FBXW7 MDM2 MGMT
9 integument MP:0010771 10.01 AKT1 APC CDKN2A FBXW7 MDM2 MLH1
10 neoplasm MP:0002006 10 AKT1 APC CDKN2A FBXW7 MDM2 MGMT
11 liver/biliary system MP:0005370 9.91 AKT1 APC CDKN2A FBXW7 MDM2 RASSF1
12 nervous system MP:0003631 9.85 AKT1 APC CDKN2A FBXW7 MDM2 MGMT
13 reproductive system MP:0005389 9.56 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
14 respiratory system MP:0005388 9.17 AKT1 CDKN2A FBXW7 MGMT MLH1 TP53

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
2
Fluorouracil Approved Phase 2 51-21-8 3385
3
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
4 Antineoplastic Agents, Immunological Phase 2
5 Mitomycins Phase 2
6 Immunosuppressive Agents Phase 2
7 Antibiotics, Antitubercular Phase 2
8 Immunologic Factors Phase 2
9 Alkylating Agents Phase 2
10 Antimetabolites Phase 2
11 Anti-Bacterial Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
2 A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons Recruiting NCT02437851 Phase 2
3 A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Recruiting NCT04166318 Phase 2 Capecitabine;Fluorouracil;Mitomycin
4 Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Completed NCT02145416
5 Microsatellite Instability in Anal Squamous Cell Carcinomas of HIV-Positive Versus HIV-Negative Patients Completed NCT00952874
6 A Study to Screen for Anal Precancerous Squamous Intraepithelial Lesions and to Prevent Anal Cancer in a Real-life Setting of People Living With HIV at Different Risk: the Seville HIV Anal Cohort Enrolling by invitation NCT03713229
7 Proton Versus Photon Therapy in Anal Squamous Cell Carcinoma - Swedish Anal Carcinoma Study Not yet recruiting NCT04462042

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

Anatomical Context for Anal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

40
Lung, Breast, Bone, Thyroid, Ovary, Colon, Cervix

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 439)
# Title Authors PMID Year
1
Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study. 61
33556252 2021
2
Anal cancer and precancerous lesions: a call for improvement. 61
33714370 2021
3
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. 61
33795829 2021
4
A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma. 61
33789221 2021
5
Anal squamous cell carcinoma incidentally found at hemorrhoidectomy. 61
33004218 2021
6
The impact of gender and HPV status on anal squamous cell carcinoma survival. 61
33787999 2021
7
Optimal Radiotherapy Dose in Anal Cancer: Trends in Prescription Dose and Association with Survival. 61
32152823 2021
8
Anal cancer survival: a socioeconomic analysis. 61
33645271 2021
9
Papillary immature squamous metaplasia of the anal canal: a rare but probably underdiagnosed entity. 61
33756001 2021
10
Evaluating the efficacy of treatment options for anal intraepithelial neoplasia: a systematic review. 61
32979069 2021
11
The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation. 61
33562397 2021
12
State of the art treatment for stage I to III anal squamous cell carcinoma: A systematic review and meta-analysis. 61
33549645 2021
13
Episomal HPV16 responsible for aggressive and deadly metastatic anal squamous cell carcinoma evidenced in peripheral blood. 61
33633240 2021
14
Interobserver variability in clinical target volume delineation in anal squamous cell carcinoma. 61
33531643 2021
15
Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status. 61
33483624 2021
16
Radiotherapy alone versus chemoradiotherapy for stage I anal squamous cell carcinoma: a systematic review and meta-analysis. 61
33486535 2021
17
Racial disparities in receipt of standard chemoradiation in anal squamous cell carcinoma, an analysis of the National Cancer Database. 61
33305908 2021
18
Tailoring the radiotherapy approach in patients with anal squamous cell carcinoma based on inguinal sentinel lymph node biopsy. 61
32964456 2021
19
Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years. 61
33498165 2021
20
Risk factors for ≥high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments. 61
33534790 2021
21
Gracilis Muscle Flap After Superficial Inguinal Lymphadenectomy in an Irradiated Inguinal Field. 61
33502213 2021
22
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma. 61
33430396 2021
23
Predicting pathological response to chemoradiotherapy for rectal cancer: a systematic review. 61
33356679 2021
24
Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: A systematic review and meta-analysis. 61
32343489 2020
25
Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy. 61
33017484 2020
26
Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer. 61
33137590 2020
27
Survival and Operative Outcomes After Salvage Surgery for Recurrent or Persistent Anal Cancer. 61
33486907 2020
28
Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. 61
32827337 2020
29
A Prospective Study of Diffusion-weighted Magnetic Resonance Imaging as an Early Prognostic Biomarker in Chemoradiotherapy in Squamous Cell Carcinomas of the Anus. 61
33023818 2020
30
In reply to letter to the editor: radiomic feature analysis of pre-treatment FDG PET-CT for predicting outcome in anal squamous cell carcinoma. 61
32361808 2020
31
Radiomic feature analysis of pre-treatment FDG PET-CT for predicting outcome in anal squamous cell carcinoma. 61
32277248 2020
32
Racial Disparities in Time to Treatment Initiation and Outcomes for Early Stage Anal Squamous Cell Carcinoma. 61
32804778 2020
33
Inguinal Lymph Node Dissection Does Not Improve Overall Survival in Anal Cancer Nodal Disease. 61
32540576 2020
34
Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs. 61
32822831 2020
35
DPD testing in radical chemoradiation for anal squamous cell carcinoma. 61
32739406 2020
36
Anal dysplasia as an incidental finding: the importance of specimen evaluation. 61
32640480 2020
37
Anal Adenocarcinoma: A Rare Malignancy in Need of Multidisciplinary Management. 61
33049179 2020
38
Prevalence and Association of Perianal and Intra-Anal Warts with Composite High-Grade Squamous Intraepithelial Lesions Among Gay and Bisexual Men: Baseline Data from the Study of the Prevention of Anal Cancer. 61
32955927 2020
39
Significance of HPV16 Viral Load Testing in Anal Cancer. 61
32266586 2020
40
High-Resolution Anoscopy Surveillance After Anal Squamous Cell Carcinoma: High-Grade Squamous Intraepithelial Lesion Detection and Treatment May Influence Local Recurrence. 61
32969879 2020
41
The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas. 61
33045147 2020
42
Diagnosis and Treatment of Anal Squamous Cell Carcinoma. 61
32969877 2020
43
Management of anal intraepithelial neoplasia and anal squamous cell carcinoma at a tertiary referral centre with a dedicated infectious diseases unit: an 18-year review. 61
32500433 2020
44
Expert Commentary on Diagnosis and Treatment of Anal Squamous Cell Carcinoma. 61
32969878 2020
45
Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. 61
32799569 2020
46
How I treat anal squamous cell carcinoma. 61
32883674 2020
47
Chemoradiation versus local excision in treatment of stage I anal squamous cell carcinoma: A population-based analysis. 61
32199768 2020
48
Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials. 61
32957741 2020
49
Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer patients. 61
32884036 2020
50
Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients. 61
32390297 2020

Variations for Anal Squamous Cell Carcinoma

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.94 TP53 PIK3CA MDM2 APC AKT1
2
Show member pathways
12.91 TP73 TP53 MLH1 MDM2 CDKN2A AKT1
3
Show member pathways
12.89 TP53 PIK3CA MDM2 CDKN2A AKT1
4
Show member pathways
12.77 TP73 TP53 PIK3CA MDM2 AKT1
5
Show member pathways
12.73 TP53 PIK3CA MLH1 CDKN2A APC AKT1
6
Show member pathways
12.65 TP73 TP53 PIK3CA APC AKT1
7
Show member pathways
12.65 TP73 TP53 PIK3CA MDM2 CDKN2A AKT1
8 12.65 TP53 RASSF1 PIK3CA MLH1 MDM2 CDKN2A
9
Show member pathways
12.64 TP53 PIK3CA MLH1 MDM2 CDKN2A APC
10
Show member pathways
12.6 TP53 RASSF1 PIK3CA MDM2 CDKN2A AKT1
11
Show member pathways
12.53 TP53 MDM2 CDKN2A AKT1
12
Show member pathways
12.46 TP53 PIK3CA APC AKT1
13
Show member pathways
12.46 TP53 PIK3CA MDM2 AKT1
14 12.45 TP53 RASSF1 PIK3CA MDM2 CDKN2A APC
15
Show member pathways
12.4 TP53 PIK3CA MDM2 AKT1
16 12.38 TP73 TP53 MLH1 MGMT MDM2 CDKN2A
17 12.37 TP53 PIK3CA MDM2 AKT1
18
Show member pathways
12.36 TP53 PIK3CA MDM2 AKT1
19
Show member pathways
12.34 TP73 TP53 MDM2 CDKN2A
20 12.32 TP53 MDM2 CDKN2A APC
21 12.3 TP53 PIK3CA CDKN2A AKT1
22
Show member pathways
12.29 TP53 PIK3CA MDM2 APC AKT1
23 12.26 TP53 PIK3CA MDM2 AKT1
24 12.26 TP53 PIK3CA MDM2 CDKN2A
25
Show member pathways
12.19 TP53 PIK3CA MDM2 AKT1
26 12.14 TP53 MLH1 APC AKT1
27 12.09 TP53 PIK3CA MDM2 CDKN2A AKT1
28 12.04 TP53 PIK3CA AKT1
29
Show member pathways
12.03 PIK3CA MDM2 AKT1
30
Show member pathways
11.99 TP73 TP53 AKT1
31
Show member pathways
11.98 TP53 PIK3CA AKT1
32 11.98 TP53 PIK3CA MDM2 AKT1
33 11.98 TP73 TP53 MLH1 MDM2 APC
34 11.96 TP53 PIK3CA AKT1
35 11.91 TP53 MDM2 CDKN2A
36 11.84 TP53 PIK3CA AKT1
37 11.84 PIK3CA MDM2 AKT1
38
Show member pathways
11.8 TP73 TP53 MDM2
39 11.77 TP53 MDM2 AKT1
40
Show member pathways
11.73 TP53 MDM2 CDKN2A AKT1
41 11.72 TP53 RASSF1 MDM2 CDKN2A
42 11.7 TP53 PIK3CA AKT1
43 11.68 TP53 MGMT MDM2 CDKN2A APC AKT1
44
Show member pathways
11.66 TP53 PIK3CA AKT1
45 11.66 TP53 PIK3CA FBXW7 AKT1
46 11.58 TP53 RASSF1 MDM2 AKT1
47
Show member pathways
11.55 TP53 MDM2 AKT1
48 11.55 TP53 MDM2 CDKN2A
49 11.47 TP53 MDM2 AKT1
50 11.39 TP53 PIK3CA MDM2 APC AKT1

GO Terms for Anal Squamous Cell Carcinoma

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.73 ZNF599 TP73 TP53 RITA1 RASSF1 MLH1
2 protein-containing complex GO:0032991 9.55 TP53 MDM2 FBXW7 CDKN2A AKT1
3 nucleoplasm GO:0005654 9.36 TP73 TP53 TASOR2 RITA1 MLH1 MGMT

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.98 TP73 TP53 MDM2 CDKN2A AKT1
2 cell cycle GO:0007049 9.95 TP73 TP53 RASSF1 MLH1 CDKN2A
3 negative regulation of gene expression GO:0010629 9.86 TP53 MDM2 FBXW7 AKT1
4 response to drug GO:0042493 9.83 TP73 TP53 MGMT MDM2
5 cellular response to hypoxia GO:0071456 9.8 TP53 MDM2 AKT1
6 protein-containing complex assembly GO:0065003 9.79 TP53 MDM2 APC
7 protein stabilization GO:0050821 9.76 TP53 RASSF1 FBXW7 CDKN2A
8 positive regulation of apoptotic process GO:0043065 9.72 TP73 TP53 CDKN2A APC AKT1
9 Ras protein signal transduction GO:0007265 9.69 TP53 RASSF1 CDKN2A
10 cellular response to organic cyclic compound GO:0071407 9.67 MGMT MDM2 AKT1
11 positive regulation of protein export from nucleus GO:0046827 9.63 TP53 MDM2
12 apoptotic mitochondrial changes GO:0008637 9.61 CDKN2A AKT1
13 replicative senescence GO:0090399 9.61 TP53 CDKN2A
14 protein destabilization GO:0031648 9.61 MDM2 FBXW7 CDKN2A
15 negative regulation of macroautophagy GO:0016242 9.6 PIK3CA AKT1
16 cardiac septum morphogenesis GO:0060411 9.59 TP53 MDM2
17 amyloid fibril formation GO:1990000 9.58 MDM2 CDKN2A
18 negative regulation of Notch signaling pathway GO:0045746 9.58 RITA1 FBXW7 AKT1
19 mammary gland epithelial cell differentiation GO:0060644 9.57 MGMT AKT1
20 anoikis GO:0043276 9.54 PIK3CA AKT1
21 cellular response to UV-C GO:0071494 9.48 TP53 MDM2
22 regulation of signal transduction by p53 class mediator GO:1901796 9.46 TP73 TP53 MDM2 AKT1
23 positive regulation of cell cycle arrest GO:0071158 9.43 TP73 TP53 CDKN2A
24 cellular response to actinomycin D GO:0072717 9.37 TP53 MDM2
25 cell cycle arrest GO:0007050 9.35 TP73 TP53 RASSF1 CDKN2A APC
26 cellular response to DNA damage stimulus GO:0006974 9.23 TP73 TP53 RASSF1 MLH1 MGMT FBXW7

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.73 TP53 MLH1 MDM2 AKT1
2 protein kinase binding GO:0019901 9.65 TP73 TP53 CDKN2A APC AKT1
3 ubiquitin protein ligase binding GO:0031625 9.62 TP53 MDM2 FBXW7 APC
4 protein N-terminus binding GO:0047485 9.54 TP53 RASSF1 MDM2
5 SUMO transferase activity GO:0019789 9.4 MDM2 CDKN2A
6 disordered domain specific binding GO:0097718 9.33 TP53 MDM2 CDKN2A
7 p53 binding GO:0002039 9.26 TP73 TP53 MDM2 CDKN2A
8 MDM2/MDM4 family protein binding GO:0097371 8.8 TP73 TP53 CDKN2A

Sources for Anal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....